Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

Hims & Hers Health’s second quarter results were met with a significant negative market reaction, as sales growth lagged Wall Street’s expectations despite a strong rise in non-GAAP profitability.

In Q2 2025, Hims & Hers reported adjusted earnings of $0.17 per share, topping estimates of $0.15. Revenue rose 73% year-over ...

We recently published 10 Stocks That Vanished in Value Hims & Hers Health, Inc. (NYSE:HIMS) is one of the worst-performing ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Dudum is still the largest individual holder of Hims & Hers’ stock, with the latest Form 4 showing that he owned 8 million ...

Insiders have been trading these 5 stocks: (($UAL)), (($DVN)), (($DDOG)), (($HIMS)) and (($FUBO)). Here is a breakdown of ...

Hims & Hers Health CEO Andrew Dudum said that the telehealth platform will continue to sell a compounded version of semaglutide. Read more here.

Andrew Dudum, Hims chief executive, said there was a “huge opportunity” in obesity as he announced the acquisition of European rival Zava, which already sells some weight-loss treatments.